← Search & browse all drugs
NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Succinimide derivatives
phensuximide
N03AD02
Adult Dosing
- Initial: 0.5 g to 1.0 g daily administered in divided doses
- Maintenance: Titrated according to response, typically up to 1.5 g to 3.0 g daily in divided doses
Pediatric Dosing
- Children 3 years and older: Initial 0.5 g daily administered in divided doses
- Maintenance: Titrated based on clinical response and tolerability
Indications
- Management of absence seizures (petit mal epilepsy)
Mechanism of Action
- Succinimide anticonvulsant that depresses the motor cortex and elevates the threshold of CNS to convulsive stimuli
- Induction of T-type calcium currents in thalamic neurons
Contraindications
- Hypersensitivity to succinimide derivatives
- Bone marrow depression or blood dyscrasias
Adverse Reactions
- Drowsiness, dizziness, headache, ataxia
- Nausea, vomiting, anorexia, abdominal pain
- Leukopenia, agranulocytosis, aplastic anemia, pancytopenia
- Rash, urticaria, Stevens-Johnson syndrome
- Lethargy, fatigue, dreaming
Drug Interactions
- Central nervous system depressants (alcohol, sedatives, tranquilizers) increase CNS depression
- Concomitant use with other anticonvulsants may alter serum concentration profiles
Curated Content: Needs Vetting Before Put to Clinical Use